the staff of the Ridgewood blog
Ridgewood NJ, according to Johns Hopkins Center for Health Security , the US FDA issued an Emergency Use Authorization (EUA) for another monoclonal antibody treatment for COVID-19. The newest EUA is for a combination therapy using casirivimab and imdevimab, developed by Regeneron Pharmaceuticals, which are monoclonal antibodies that target the receptor binding domain for the SARS-CoV-2 spike protein. Similar to the previous FDA EUA for the Eli Lilly monoclonal antibody treatment, this combination is authorized for use in mild or moderate COVID-19 patients (aged 12 years and older) who are not currently hospitalized but who are at high risk of progressing to severe disease. It is not authorized for patients who are currently hospitalized or receiving supplemental oxygen therapy for COVID-19 or an underlying health condition. The 2 products must be administered together.
Continue reading Regeneron COVID Antibody Treatment Gets Emergency Use Authorization from the FDA
